CVS Group plc (LON:CVSG)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 865.73M -3.8% |
| Revenue (ttm) | 692.80M +7.1% |
| Net Income | 49.40M +997.8% |
| EPS | 0.69 +1,002.4% |
| Shares Out | 70.16M |
| PE Ratio | 53.88 |
| Forward PE | 13.62 |
| Dividend | 0.09 (0.69%) |
| Ex-Dividend Date | Nov 6, 2025 |
| Volume | 436,657 |
| Open | 1,226.50 |
| Previous Close | 1,234.00 |
| Day's Range | 1,214.00 - 1,240.00 |
| 52-Week Range | 1,062.00 - 1,648.00 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 1,639.50 (+32.97%) |
| Earnings Date | Sep 24, 2026 |
About CVS Group
CVS Group plc, together with its subsidiaries, engages in veterinary, online pharmacy, and retail businesses in the United Kingdom and Australia. It operates through the Veterinary Practices, Laboratories, and Online Retail Business segments. The company is involved in animal veterinary practices and complementary veterinary diagnostic businesses. It also operates Animed Direct, an online retail business that sells prescription and non-prescription medicines, pet foods, and other pet care products, as well as an online dispensary. In addition, ... [Read more]
Financial Performance
In fiscal year 2025, CVS Group's revenue was 673.20 million, an increase of 5.40% compared to the previous year's 638.70 million. Earnings were 52.80 million, an increase of 751.61%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CVSG stock is "Buy." The 12-month stock price target is 1,640p, which is an increase of 32.97% from the latest price.
News
Converium Capital Inc.: Converium Capital Sends Letter to CVS Group Board Highlighting Company's Undervaluation and Urging £100 Million Share Buyback
Follows Extensive Private Engagement That Has Not Produced Meaningful Action Converium Capital Inc. ("Converium"), which manages funds that own shares of CVS Group plc (LSE: CVSG) ("CVS Group" or ...
Converium Capital Sends Letter to CVS Group Board Highlighting Company's Undervaluation and Urging £100 Million Share Buyback
MONTREAL--(BUSINESS WIRE)--Converium Capital Inc. (“Converium”), which manages funds that own shares of CVS Group plc (LSE: CVSG) (“CVS Group” or the “Company”), today announced that it has sent a let...
UK's CVS Group CEO to step down after 7 years at the helm
British veterinary services provider CVS Group said on Monday CEO Richard Fairman plans to retire after seven years in the role.
CVS Group initiated with an Equal Weight at Barclays
Barclays initiated coverage of CVS Group (CVSGF) with an Equal Weight rating and 1,340 GBp price target The firm cites competitive dynamics in the UK merger market and the weak
Half Year 2026 CVS Group PLC Earnings Presentation Transcript
Half Year 2026 CVS Group PLC Earnings Presentation Transcript
CVS Group Earnings Call Transcript: H1 2026
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and successful rebranding and regulatory compliance initiatives. UK and Australia acquisition pipelines remain robust, supporting a positive outlook.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.
CVS Group Slides: H1 2026
CVS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CVS Group Earnings Call Transcript: H1 2026
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.
CVS Group Slides: H1 2026
CVS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CVS Group Earnings release: Q2 2026
CVS Group released its Q2 2026 earnings on January 23, 2026, summarizing the period's financial results.
CVS Group Earnings release: Trading Update
CVS Group released its earnings on November 18, 2025, summarizing the period's financial results.
UK's CVS Group plans Main Market move, approves near $27 million buyback
Veterinary services provider CVS Group said on Friday it plans to move its listing from the Alternative Investment Market to the London Stock Exchange's Main Market, while also approving a new 20 mill...
CVS Group Transcript: Investor Update
Revenue rose 5.4% to £673.2m and adjusted EBITDA grew 9.4%, with strong cash generation and leverage reduced to 1.18x. Expansion in Australia continues, UK acquisitions are set to resume post-CMA, and medium-term like-for-like growth guidance is 4–8%.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to £673.2m, with adjusted EBITDA up 9.4% and margin at 20%. Australian expansion continued, and UK operations improved, with strong cash flow and reduced leverage. Confident in medium-term 4%-8% growth, supported by efficiency gains and selective acquisitions.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.
CVS Group Slides: H2 2025
CVS Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on October 7, 2025.
CVS Group Earnings Call Transcript: H2 2025
Revenue grew 5.4% to GBP 673.2 million, with Adjusted EBITDA up 9.4% and margin at 20%. Strong cash flow, reduced leverage, and continued expansion in Australia position the group for further growth, despite ongoing CMA investigation and sector headwinds.
CVS Group Annual report: H2 2025
CVS Group has published its H2 2025 annual report on October 7, 2025.
CVS Group Slides: H2 2025
CVS Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on October 7, 2025.
CVS Group Earnings release: Q4 2025
CVS Group released its Q4 2025 earnings on July 24, 2025, summarizing the period's financial results.
CVS Group Earnings Call Transcript: H1 2025
Revenue rose 6.6% to £341.8m and EBITDA grew 4.5% to £67.4m, with strong expansion in Australia and ongoing UK regulatory uncertainty. The business remains confident in its five-year EBITDA doubling plan and targets a 23% margin by 2027, supported by operational synergies and disciplined capital allocation.
CVS Group Quarterly report: H1 2025
CVS Group has published its H1 2025 quarterly earnings report on February 27, 2025.